Thumkar Surappa Shylasree
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Thumkar Surappa Shylasree has a total of 127 co-authors. Here are the top co-authors by number of shared publications:
Amita Maheshwari
Department of Gynaecological Oncology, Gynaecology Oncology Disease Management Group, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India
7 shared publications- Jaya Ghosh
Department of Radiation Oncology, Clinical Research Centre, Advanced Centre for Treatment Research and Education in Cancer (ACTREC), Tata Memorial Centre, Homi Bhabha National Institute, Kharghar, Navi Mumbai, Maharashtra, India
5 shared publications - Pabashi Poddar
Department of Gynecological Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India
5 shared publications - Seema Gulia
Department of Medical Oncology Tata Memorial Centre, Homi Bhabha National Institute Mumbai India
5 shared publications - Amita Maheshwari
Division of Gynecologic Oncology Tata Memorial Centre, Homi Bhabha National Institute Mumbai India
4 shared publications Biswajit Dash
Department of Gynaecological Oncology, Gynaecology Oncology Disease Management Group, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India
4 shared publications
Latest Publications
- Open Access
- 6 November 2025
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 17 (7) , 1-6
Insights into Growing Teratoma Syndrome: An In-Depth Retrospective Analysis of Clinical Features and Treatment Outcomes
Growing teratoma syndrome (GTS) is a rare clinical condition occurring in women with malignant ovarian germ cell tumors, with paradoxical findings of normal serum tumor markers and enlarging metastatic lesions during the adjuvant chemotherapy and/or follow-up period. The appropriate management is complete surgical resection and is currently the standard of care. We aim to evaluate the surgical and oncological outcomes and follow-up of patients with GTS. A retrospective analysis of clinicopathological outcomes of patients undergoing treatment for GTS between 2014 and 2021 was conducted. Patient demographics and clinical characteristics were calculated using descriptive analysis. Survival estimates for overall survival and disease-free survival are obtained using the Kaplan-Meier method. OS and time to recurrence in GTS between two or more groups are compared using the log rank test. A two-tailed p value less than 0.05 was considered statistically significant. A total of 32 cases were included. Around 70% were stage I/II at initial diagnosis, and 60% progressed to GTS during the course of chemotherapy. Surgery was done in 27 cases. The presence of residual disease at surgery for GTS and initial stage were found to be significant predictors for overall survival and time to recurrence in GTS. GTS is a rare entity, and treatment is individualized based on several factors. A complete cytoreduction is the most important predictor for survival in these patients.
- 6 November 2025
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 17 (7) , 1-6
Open AccessInsights into Growing Teratoma Syndrome: An In-Depth Retrospective Analysis of Clinical Features and Treatment Outcomes
Growing teratoma syndrome (GTS) is a rare clinical condition occurring in women with malignant ovarian germ cell tumors, with paradoxical findings of normal serum tumor markers and enlarging metastatic lesions during the adjuvant chemotherapy and/or follow-up period. The appropriate management is complete surgical resection and is currently the standard of care. We aim to evaluate the surgical and oncological outcomes and follow-up of patients with GTS. A retrospective analysis of clinicopathological outcomes of patients undergoing treatment for GTS between 2014 and 2021 was conducted. Patient demographics and clinical characteristics were calculated using descriptive analysis. Survival estimates for overall survival and disease-free survival are obtained using the Kaplan-Meier method. OS and time to recurrence in GTS between two or more groups are compared using the log rank test. A two-tailed p value less than 0.05 was considered statistically significant. A total of 32 cases were included. Around 70% were stage I/II at initial diagnosis, and 60% progressed to GTS during the course of chemotherapy. Surgery was done in 27 cases. The presence of residual disease at surgery for GTS and initial stage were found to be significant predictors for overall survival and time to recurrence in GTS. GTS is a rare entity, and treatment is individualized based on several factors. A complete cytoreduction is the most important predictor for survival in these patients.
- Open Access
- 6 December 2024
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 16 (3) , 799-806
Prognostic Factors for Vulvar Cancer Undergoing Primary Surgery: Case Series from a Single Tertiary Cancer Center
To evaluate clinical outcomes in women undergoing primary surgery for vulvar squamous cell carcinoma) (SCC) with an aim to identify surgico-pathological risk factors associated with recurrence and survival. Retrospective cohort analysis was carried out between January 2011 and December 2018 for patients with vulvar SCC who underwent primary surgery. The Kaplan–Meier method was used for the estimation of the probability of disease-free survival (DFS) and overall survival (OS). Univariate and multivariate analyses based on the Cox proportional hazards model were performed to identify factors associated with DFS and OS. A p-value ≤ 0.05 in a two-tailed test was considered statistically significant. The study population included 81 patients; the median follow-up time for the entire cohort was 41 months. Recurrence was noted in 27 cases (33.3%), and the median time to recurrence was 36.14 months. The median overall survival (OS) was 40.8 months, and disease-free survival (DFS) was 36 months. On univariate analysis, depth of invasion (DOI), close margin, presence of lympho-vascular space invasion (LVSI), perineural invasion (PNI), groin metastases, and not receiving adjuvant therapy were significantly associated with increased recurrence rates. Deeper stromal invasion, presence of LVSI, groin node metastases, and recurrent disease were associated with poor OS on univariate analysis. On multivariate analysis, DOI, tumor-free margin (TFM), and PNI were significantly associated with DFS, and a previous history of recurrence was associated with OS. Vulvar cancers are relatively rare tumors with several local tumor factors such as TFM, DOI, LVSI, and lymph node status which may help determine oncological outcomes. Larger studies will definitely help establish more evidence.
- 6 December 2024
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 16 (3) , 799-806
Open AccessPrognostic Factors for Vulvar Cancer Undergoing Primary Surgery: Case Series from a Single Tertiary Cancer Center
To evaluate clinical outcomes in women undergoing primary surgery for vulvar squamous cell carcinoma) (SCC) with an aim to identify surgico-pathological risk factors associated with recurrence and survival. Retrospective cohort analysis was carried out between January 2011 and December 2018 for patients with vulvar SCC who underwent primary surgery. The Kaplan–Meier method was used for the estimation of the probability of disease-free survival (DFS) and overall survival (OS). Univariate and multivariate analyses based on the Cox proportional hazards model were performed to identify factors associated with DFS and OS. A p-value ≤ 0.05 in a two-tailed test was considered statistically significant. The study population included 81 patients; the median follow-up time for the entire cohort was 41 months. Recurrence was noted in 27 cases (33.3%), and the median time to recurrence was 36.14 months. The median overall survival (OS) was 40.8 months, and disease-free survival (DFS) was 36 months. On univariate analysis, depth of invasion (DOI), close margin, presence of lympho-vascular space invasion (LVSI), perineural invasion (PNI), groin metastases, and not receiving adjuvant therapy were significantly associated with increased recurrence rates. Deeper stromal invasion, presence of LVSI, groin node metastases, and recurrent disease were associated with poor OS on univariate analysis. On multivariate analysis, DOI, tumor-free margin (TFM), and PNI were significantly associated with DFS, and a previous history of recurrence was associated with OS. Vulvar cancers are relatively rare tumors with several local tumor factors such as TFM, DOI, LVSI, and lymph node status which may help determine oncological outcomes. Larger studies will definitely help establish more evidence.
- 30 August 2024
- Published by Springer Nature
- p. 763-775
Uterine Cancer
- 30 August 2024
- Published by Springer Nature
- p. 795-808
Vulvar and Vaginal Cancers
- 24 November 2023
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 15 (1) , 88-94
Clinicopathological and Oncological Outcomes of Borderline Mucinous Tumours of Ovary: a Large Case Series
The objective is to study the clinico-demographic profile, treatment patterns and oncological outcomes in borderline mucinous tumours of the ovary. Retrospective cohort analysis was carried out between January 2017 and December 2019 for patients with a diagnosis of borderline mucinous tumours of the ovary who were treated at our centre. Kaplan–Meier method was used for the estimation of the probability of DFS and OS. Univariate and multivariate analyses based on the Cox proportional hazard model were performed to identify factors associated with DFS and OS. A p-value ≤ 0.05 in a two-tailed test was considered statistically significant. The study population included 75 patients and the median follow-up time for the entire cohort was 24 months. The 5-year DFS for the entire cohort was 79.6% and OS was 90.5%, whereas for stage I disease, 5-year OS was 92.6% as opposed to 60% in the advanced stage. On univariate analysis, only the stage of the disease had a significant association with DFS and OS. Fertility-preserving surgeries had no impact on OS or DFS, and hence, it is suggested that fertility-sparing surgeries may be considered a viable option in young patients with mucinous ovarian tumours. Borderline mucinous tumours of the ovary have excellent survival outcomes and fertility-sparing surgeries should be done whenever feasible.
- 24 November 2023
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 15 (1) , 88-94
Clinicopathological and Oncological Outcomes of Borderline Mucinous Tumours of Ovary: a Large Case Series
The objective is to study the clinico-demographic profile, treatment patterns and oncological outcomes in borderline mucinous tumours of the ovary. Retrospective cohort analysis was carried out between January 2017 and December 2019 for patients with a diagnosis of borderline mucinous tumours of the ovary who were treated at our centre. Kaplan–Meier method was used for the estimation of the probability of DFS and OS. Univariate and multivariate analyses based on the Cox proportional hazard model were performed to identify factors associated with DFS and OS. A p-value ≤ 0.05 in a two-tailed test was considered statistically significant. The study population included 75 patients and the median follow-up time for the entire cohort was 24 months. The 5-year DFS for the entire cohort was 79.6% and OS was 90.5%, whereas for stage I disease, 5-year OS was 92.6% as opposed to 60% in the advanced stage. On univariate analysis, only the stage of the disease had a significant association with DFS and OS. Fertility-preserving surgeries had no impact on OS or DFS, and hence, it is suggested that fertility-sparing surgeries may be considered a viable option in young patients with mucinous ovarian tumours. Borderline mucinous tumours of the ovary have excellent survival outcomes and fertility-sparing surgeries should be done whenever feasible.
- Open Access
- 12 July 2023
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 48, 101241
Novel educational training of para medical professionals in cervical cancer screening
- 12 July 2023
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 48, 101241
Open AccessNovel educational training of para medical professionals in cervical cancer screening
- 12 June 2023
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 14 (4) , 809-821
Synchronous and Metachronous Breast and Ovarian Cancers: Experience from a Single Tertiary Care Cancer Centre in India
Women with either breast cancer (BC) or ovarian cancer (OC) have a 1.5–2 times higher risk of developing the other. Discerning discrete primaries versus metastases from either can be challenging. Clinico-pathological and outcome details of patients diagnosed with both BC and OC from December 1994 to August 2018 were retrospectively evaluated at a single tertiary cancer centre. We report the pattern of presentation and recurrences with case-based illustrations. Out of 139 patients, presentation was BC-first in 66.2%, OC-first in 24.5% and synchronous cancers (SC) in 9.3% of women. The median age at diagnosis in BC-first, OC-first and SC was 42 years, 48 years and 49 years, respectively. The most common histological subtype was invasive breast carcinoma-no special type (74.8%) in BC and serous cystadenocarcinoma (81.3%) in OC. BC presented at an early stage in 67.6% while OC presented at an advanced stage in 48.2% of patients. Germline mutation results were available in 82% with 61.4% of the cohort exhibiting a mutation- BRCA1 mutation being the most common. The median time to development of second cancer was 77.4 months and 39.4 months in BC-first and OC-first, respectively. At a median follow-up of 9.47 years, disease-free survival was 32.6%, 32.4% and 30.8% in BC-first, OC-first and SC, respectively (p < 0.001). In hereditary breast and ovarian cancer, BC-first patients have a better prognosis while synchronous malignancies have worse oncological outcomes. Deaths are mainly due to OC progression. Appropriate surveillance and prophylactic intervention in young patients with breast cancer may improve overall outcomes.
- 12 June 2023
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 14 (4) , 809-821
Synchronous and Metachronous Breast and Ovarian Cancers: Experience from a Single Tertiary Care Cancer Centre in India
Women with either breast cancer (BC) or ovarian cancer (OC) have a 1.5–2 times higher risk of developing the other. Discerning discrete primaries versus metastases from either can be challenging. Clinico-pathological and outcome details of patients diagnosed with both BC and OC from December 1994 to August 2018 were retrospectively evaluated at a single tertiary cancer centre. We report the pattern of presentation and recurrences with case-based illustrations. Out of 139 patients, presentation was BC-first in 66.2%, OC-first in 24.5% and synchronous cancers (SC) in 9.3% of women. The median age at diagnosis in BC-first, OC-first and SC was 42 years, 48 years and 49 years, respectively. The most common histological subtype was invasive breast carcinoma-no special type (74.8%) in BC and serous cystadenocarcinoma (81.3%) in OC. BC presented at an early stage in 67.6% while OC presented at an advanced stage in 48.2% of patients. Germline mutation results were available in 82% with 61.4% of the cohort exhibiting a mutation- BRCA1 mutation being the most common. The median time to development of second cancer was 77.4 months and 39.4 months in BC-first and OC-first, respectively. At a median follow-up of 9.47 years, disease-free survival was 32.6%, 32.4% and 30.8% in BC-first, OC-first and SC, respectively (p < 0.001). In hereditary breast and ovarian cancer, BC-first patients have a better prognosis while synchronous malignancies have worse oncological outcomes. Deaths are mainly due to OC progression. Appropriate surveillance and prophylactic intervention in young patients with breast cancer may improve overall outcomes.
- Open Access
- 9 June 2023
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 33 (8) , 1329-1330
Field-cycling imaging in ovarian cancer: a novel technology
- 9 June 2023
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 33 (8) , 1329-1330
Open AccessField-cycling imaging in ovarian cancer: a novel technology
- 5 June 2023
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 14 (4) , 784-792
Clinical Observations and Outcomes in Advanced Low-Grade Serous Carcinoma of the Ovary: Case Series from a Tertiary Cancer Center
Low-grade serous carcinoma (LGSC) is a rare histologic subtype of ovarian cancer. We present detailed management of 15 cases of advanced LGSC from a tertiary cancer center of India. Fifteen cases of advanced LGSC who underwent cytoreductive surgery (CRS) were analyzed from a prospectively maintained database. Baseline demographic characteristics, surgical details, and chemotherapy details were recorded. Descriptive statistics were summarized, and progression-free survival (PFS) and overall survival (OS) were estimated. The median age was 37 years. Nine patients had received NACT. All cases were FIGO stage III. Mean PCI was 15. Eleven patients had a completeness of cytoreduction score of 0–1. The median surgical time was 7.5 h; nine patients required multiple gastrointestinal resections. Median blood loss was 2500 ml. Median postoperative ventilation, ICU stay, and hospital stays were 1, 2, and 16 days, respectively. One patient had a grade III complication. Four patients received adjuvant chemotherapy. There was no postoperative mortality at the end of 90 days of surgery. All the patients except one were offered hormonal maintenance therapy. At a median follow-up of 43 months, 4 patients were disease-free, 9 had a recurrence, one died of disease progression, and one was lost to follow-up. Most recurrences were locoregional in the peritoneal cavity or pelvis. Four-year OS and PFS were 71.8% and 29.7%, respectively. Advanced LGSCs occur mostly in young premenopausal women with favorable oncologic outcomes. Optimal CRS is the mainstay of treatment. Relative chemo-resistance and hormone receptor positivity provide an excellent therapeutic opportunity for endocrine therapy.
- 5 June 2023
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 14 (4) , 784-792
Clinical Observations and Outcomes in Advanced Low-Grade Serous Carcinoma of the Ovary: Case Series from a Tertiary Cancer Center
Low-grade serous carcinoma (LGSC) is a rare histologic subtype of ovarian cancer. We present detailed management of 15 cases of advanced LGSC from a tertiary cancer center of India. Fifteen cases of advanced LGSC who underwent cytoreductive surgery (CRS) were analyzed from a prospectively maintained database. Baseline demographic characteristics, surgical details, and chemotherapy details were recorded. Descriptive statistics were summarized, and progression-free survival (PFS) and overall survival (OS) were estimated. The median age was 37 years. Nine patients had received NACT. All cases were FIGO stage III. Mean PCI was 15. Eleven patients had a completeness of cytoreduction score of 0–1. The median surgical time was 7.5 h; nine patients required multiple gastrointestinal resections. Median blood loss was 2500 ml. Median postoperative ventilation, ICU stay, and hospital stays were 1, 2, and 16 days, respectively. One patient had a grade III complication. Four patients received adjuvant chemotherapy. There was no postoperative mortality at the end of 90 days of surgery. All the patients except one were offered hormonal maintenance therapy. At a median follow-up of 43 months, 4 patients were disease-free, 9 had a recurrence, one died of disease progression, and one was lost to follow-up. Most recurrences were locoregional in the peritoneal cavity or pelvis. Four-year OS and PFS were 71.8% and 29.7%, respectively. Advanced LGSCs occur mostly in young premenopausal women with favorable oncologic outcomes. Optimal CRS is the mainstay of treatment. Relative chemo-resistance and hormone receptor positivity provide an excellent therapeutic opportunity for endocrine therapy.
- 9 November 2022
- Published by Springer Nature in Indian Journal of Gynecologic Oncology
- Vol. 20 (4) , 1-4
Autologous Ovary Transplant in Pelvic Sarcoma: Two Case Reports and Review of Literature on Gonad Transplant
- 9 November 2022
- Published by Springer Nature in Indian Journal of Gynecologic Oncology
- Vol. 20 (4) , 1-4
Autologous Ovary Transplant in Pelvic Sarcoma: Two Case Reports and Review of Literature on Gonad Transplant